BIOPHARMA
By
Is Samsung Biologics Set to Expand U.S. Operations with $280 Million GSK Acquisition?
Seoul/Washington, D.C. South Korea’s Samsung Biologics has announced its acquisition of its first U.S.-based drug production facility from…
Can TrumpRx and Pfizer’s Discount Deal Reshape Prescription Drug Pricing in the U.S.?
Washington, D.C. The U.S. administration has announced the launch of TrumpRx, a federally operated digital platform designed to…
Is Sanofi Strengthening Its Adult Vaccine Strategy with a $2.2 Billion Dynavax Deal?
Paris, France Sanofi has taken a major step to strengthen its adult vaccines portfolio by announcing a $2.2…
Has Sanofi’s Dupixent Been Approved for Pediatric Asthma in Japan?
Tokyo, Japan – December 23, 2025 Sanofi and Regeneron have received regulatory approval in Japan for Dupixent (dupilumab)…
Did NVIDIA Become the Central AI Catalyst for Biopharma in 2025—And Which Players Benefited Most?
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
